Vaxxas has received a manufacturing licence from Australia’s Therapeutic Goods Administration (TGA) for its high-density microarray patch (HD-MAP) for clinical studies at a biomedical facility in Brisbane.

This development follows the installation of the company’s first robotic lines for aseptic (sterile) production.

The HD-MAP is tailored to deliver all types of vaccines to the skin using a simple applicator, with the aim of providing a universal solution for self-administration of a vaccine.